• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

eye diseases

Pharma

JPM: Novartis CEO refutes respiratory, eye drug sell-off report

Novartis is committed asthma drug Xolair and its eye disease portfolio, including gene therapies, CEO Vas Narasimhan said despite a sell-off rumor.
Angus Liu Jan 9, 2023 4:56pm

Genentech starts phase 2 trial to optimize cell therapy delivery

Nov 28, 2022 10:20am

Apellis' closely watched eye drug gets new FDA goal date

Nov 18, 2022 12:03pm

Roche touts Vabysmo toe-to-toe data against Eylea in RVO

Oct 27, 2022 10:55am

Tarsus launches campaign for misdiagnosed eyelid condition

Sep 30, 2022 11:03am

Eylea set to battle back at Roche's Vabysmo

Sep 7, 2022 6:52pm
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy